The deal is closed and the stock will be delisted. Noteholders should evaluate the conversion window (through January 8, 2027) for the make-whole premium of $1,103.89 per $1,000 principal versus the post-period conversion value of $922.54.
PCRX drugs
PCRX drug pipeline →Price Chart
How similar events traded
Executive Summary
Viatris completed its acquisition of Pacira BioSciences via a tender offer and subsequent merger. The $1.69 billion all-cash deal closed on November 17, 2026, with Pacira becoming a wholly owned subsidiary of Viatris. The filing also covers delisting from Nasdaq, termination of Pacira's credit agreement, changes to convertible note terms, and the departure of all prior directors and officers.
Key Financial Metrics
Key Facts
- Viatris completed acquisition of Pacira for $36.50 per share in cash, total consideration ~$1.69 billion
- Tender offer closed with 32,929,780 shares (66.46%) validly tendered
- Merger completed under Section 251(h) of DGCL without stockholder vote
- Pacira became a wholly owned subsidiary of Viatris at the Effective Time
- All prior directors and officers of Pacira ceased; John Miraglia and Michael Rainerman became officers/directors of the surviving corporation
- Pacira requested delisting from Nasdaq and deregistration under Section 12(b) of the Exchange Act
- $287.5 million in 2.125% Convertible Senior Notes due 2029 modified: conversion right changed to cash based on $36.50 per share
- Credit agreement with Wells Fargo repaid in full ($96,392.50) and terminated
- Capped call transactions unwound for cash payments to Pacira
- Third amended and restated certificate of incorporation and fourth amended and restated bylaws adopted
Financial Impact
Total consideration of approximately $1.69 billion for the acquisition, including repayment of certain indebtedness. $287.5 million in convertible notes outstanding; conversion rights changed to cash settlement at $36.50 per share.
Risk Factors
- Stockholder lawsuits challenging disclosure adequacy in the tender offer are pending
- Delisting from Nasdaq will eliminate liquidity for remaining public shareholders
- Convertible noteholders who do not convert within the make-whole period will receive significantly less cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-044354 |
| Document: ef20085678_8k.htm | 0001140361-26-044354 |
| Document: ef20085678_ex3-1.htm | 0001140361-26-044354 |
| Document: ef20085678_ex4-1.htm | 0001140361-26-044354 |
| Document: ef20085678_ex99-1.htm | 0001140361-26-044354 |
| Document: 0001140361-26-044354-index-headers.html | 0001140361-26-044354 |
| Document: 0001140361-26-044354-index.html | 0001140361-26-044354 |
| Document: 0001140361-26-044354.txt | 0001140361-26-044354 |
Track record
33 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 17, 20264d ago 8-K Mixed 8/10 Viewing Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago SC 14D-9/A Mixed 8/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago 25-NSE Neutral 1/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 12, 20269d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20269d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20269d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202618d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202622d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers